Xconomy -- There are lots of exceptions to the rules in the biotech business, and a big one jumped out me this past week, related to antibiotics. One day, Reuters ran a story about the overall abysmal state of the world’s pipeline of new antibiotics. Next day, there were reports about how San Diego-based Optimer Pharmaceuticals appears poised to sail through a meeting scheduled for tomorrow of an FDA advisory panel that will size up the merits of its new antibiotic.
